News

The company will continue evaluating the compound in other hematologic malignancies such as adult acute lymphoblastic leukemia (ALL). Pfizer’s oncology business unit clinical development and medical affairs senior

The transaction, if successfully completed, is expected to create a global specialty pharmaceutical company with around $11bn in combined annual revenue, and the third-largest US specialty pharmaceutical company

Following the transaction, Xellia will revert to Danish ownership with headquarters in Denmark. Xellia develops and manufactures anti-infective therapies for multi-drug resistant infections and supplies Vancomycin and Colistimethate

The recall follows the discovery of particulate matter in vials during routine quality examination of retention samples at the manufacturer. Methotrexate is an antimetabolite used in the treatment

Greens Hx product offers high density nutrition with plant extracts from 39 super foods including sea greens, soy lecithin, vegetables, herbs, spices, royal jelly, apple pectin, plant enzymes

Global Pharmaceuticals, the generics division of Impax, commenced product shipment, as part of a distribution, license, development and supply agreement with AstraZeneca UK. Zomig is indicated to treat

The trial will test the safety and efficacy of intra-articular injections of autologous human adipose-derived mesenchymal progenitor cells (haMPC) to reduce inflammation and regenerate damaged joint tissues. Cellular

IL-13 is an immune regulatory cytokine and IL-13Ra2 is highly and specifically expressed in glioblastoma, ovarian and other solid tumors, but not in normal tissue. ICT-107 is the

The partnership will leverage DBV’s skin patch, Viaskin, and Stallergenes’ expertise in respiratory allergies in developing immunotherapy treatments for respiratory allergies. DBV Technologies chairman and CEO Dr. Pierre-Henri